863 related articles for article (PubMed ID: 32918855)
1. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
2. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
3. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
[TBL] [Abstract][Full Text] [Related]
4. An Impaired Inflammatory and Innate Immune Response in COVID-19.
Park SH
Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
[TBL] [Abstract][Full Text] [Related]
5. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
[No Abstract] [Full Text] [Related]
6. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
7. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
9. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
[TBL] [Abstract][Full Text] [Related]
11. Immune dysregulation and system pathology in COVID-19.
Jamal M; Bangash HI; Habiba M; Lei Y; Xie T; Sun J; Wei Z; Hong Z; Shao L; Zhang Q
Virulence; 2021 Dec; 12(1):918-936. PubMed ID: 33757410
[TBL] [Abstract][Full Text] [Related]
12. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Gupta SP
Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
[TBL] [Abstract][Full Text] [Related]
13. SARS coronavirus 2: from genome to infectome.
Rastogi M; Pandey N; Shukla A; Singh SK
Respir Res; 2020 Dec; 21(1):318. PubMed ID: 33261606
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
15. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.
Perazzolo S; Zhu L; Lin W; Nguyen A; Ho RJY
J Pharm Sci; 2021 Mar; 110(3):1002-1017. PubMed ID: 33248057
[TBL] [Abstract][Full Text] [Related]
16. The role and delicate balance of Host Immunity in Coronavirus Disease-19.
Vyas AK; Varma V; Garg G; Gupta P; Trehanpati N
Iran J Immunol; 2021 Mar; 18(1):1-12. PubMed ID: 33787510
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
Asrani P; Hassan MI
Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
[TBL] [Abstract][Full Text] [Related]
18. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A
Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
[TBL] [Abstract][Full Text] [Related]
20. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
Egilmezer E; Rawlinson WD
Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
